This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Wisconsin Alumni Research Foundation. Active years: 2016.
Company Filing History:
Years Active: 2016
Title: Michelle Kimple: Innovator in Anti-Diabetic Therapeutics
Introduction
Michelle Kimple is a prominent inventor based in Madison, WI (US). She has made significant contributions to the field of diabetes research, particularly in the development of novel therapeutic targets for anti-diabetic treatments. Her work focuses on enhancing insulin secretion from beta cells, which is crucial for managing diabetes.
Latest Patents
Michelle Kimple holds a patent titled "E-prostanoid receptor, Ptger3, as a novel anti-diabetic therapeutic target." This patent outlines methods for increasing insulin secretion from beta cells. It also describes methods that involve administering a composition to a subject in need of increased insulin secretion. This composition comprises a compound that directly or indirectly activates adenylate cyclase and an E prostanoid 3 (EP3) receptor antagonist that mitigates G alpha-i-subfamily (GSIS)-mediated adenylate cyclase inhibition. She has 1 patent to her name.
Career Highlights
Michelle Kimple is associated with the Wisconsin Alumni Research Foundation, where she continues to advance her research in diabetes therapeutics. Her innovative approaches have garnered attention in the scientific community, contributing to the understanding of insulin secretion mechanisms.
Collaborations
Some of her notable coworkers include Mark Patrick Keller and Alan D Attie. Their collaborative efforts have further enhanced the research output and innovation in the field of diabetes treatment.
Conclusion
Michelle Kimple's work exemplifies the impact of innovative research on diabetes management. Her contributions to the field are paving the way for new therapeutic strategies that could significantly improve the lives of individuals with diabetes.